BMS-354825: Phase I data

In a U.S. Phase I trial in 65 patients resistant or intolerant to imatinib, hematologic and cytogenetic responses

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE